Price as of 19 Nov 2026 (ASX, midday): A$198.5 (ASX: CSL). Price and valuation data: StockAnalysis; results: ASX announcements.
CSL is a global biotech company built on plasma therapies (CSL Behring), influenza vaccines (Seqirus) and kidney and iron treatments (CSL Vifor). After a difficult FY26 with large write-downs, management has reset the strategy.
CSL reports in US dollars; targets here are in Australian dollars.
Related:BHP target · CBA target · Fortescue target · Woodside target · Our methodology
How CSL Makes Money
CSL has three businesses:
- CSL Behring: the largest part, making medicines from donated blood plasma — immunoglobulins for immune deficiencies and neurological conditions, albumin, and treatments for bleeding disorders such as haemophilia. Plasma is collected through CSL Plasma's network of collection centres, most of them in the US.
- CSL Seqirus: one of the world's biggest influenza vaccine makers, supplying both seasonal and pandemic vaccines.
- CSL Vifor: treatments for iron deficiency and kidney disease. Revenue is falling as some products face generic competition.
Why it matters for the targets: the key profit driver is the gross margin at CSL Behring. Collecting plasma became much more expensive after the pandemic, and margins have been recovering slowly as donor fees and costs come down and new collection technology improves yields. Our base case assumes that recovery continues; our bear case assumes it stalls and Vifor keeps shrinking.
CSL used to trade at more than 30× earnings because of reliable double-digit growth. The FY26 write-downs and slower growth have reset that valuation, which is why our bull case does not assume a full return to the old premium.
Capital returns: CSL pays dividends twice a year, declared in US dollars, and announced a further A$1 billion on-market buyback.
Table of Contents
1. CSL Share Price Targets 2027–2030 at a Glance
All three scenarios come from one formula (next section). Targets are for the end of each calendar year.
| Year-end | Bear (A$) | Base (A$) | Bull (A$) |
|---|---|---|---|
| 2027 | 166 | 202 | 239 |
| 2028 | 171 | 219 | 268 |
| 2029 | 176 | 236 | 300 |
| 2030 | 181 | 255 | 336 |
The base case implies a price change of roughly 6% a year from today's A$198.5 to the end of 2030.
2. How We Calculate These Targets
Target = projected EPS × P/E multiple. We start from the forward EPS of A$9.2 implied by the current forward P/E, treat it as FY2027 EPS, and grow it at each scenario's rate for later years. Each year-end target applies a P/E multiple to that year's EPS. Read our full methodology.
- Starting EPS: about A$9.20, implied by a 21.6× forward P/E. Trailing statutory EPS is negative because of impairments.
- Bear case: EPS grows 3% a year, P/E 18×. Plasma margins stay weak and Vifor keeps declining.
- Base case: EPS grows 8% a year, P/E 22×. Margins recover gradually and buybacks support EPS.
- Bull case: EPS grows 12% a year, P/E 26×. Plasma margins return to historical levels and the premium returns.
| Financial year | Bear EPS (A$) | Base EPS (A$) | Bull EPS (A$) |
|---|---|---|---|
| FY2027 | 9.20 | 9.20 | 9.20 |
| FY2028 | 9.48 | 9.94 | 10.30 |
| FY2029 | 9.76 | 10.73 | 11.54 |
| FY2030 | 10.05 | 11.59 | 12.93 |
Worked example (base, 2027): A$9.2 = A$9.20 FY2027 EPS → × 22 = A$202.
Sensitivity — 2030 base-case EPS of A$11.59 at different multiples:
| P/E | 18× | 22× | 26× |
|---|---|---|---|
| 2030 price (A$) | 209 | 255 | 301 |
3. Latest Results: What Changed
| FY2026 | Value | Change |
|---|---|---|
| Revenue | US$15.8 billion | -1% (constant currency) |
| Underlying NPATA | US$3.1 billion | -2% |
| Pre-tax impairments | US$7.1 billion | — |
| FY27 underlying NPAT guidance | ~+5% | — |
| New buyback | A$1 billion | — |
Revenue was US$15.8 billion and underlying profit fell 2% to US$3.1 billion. Impairments of US$7.1 billion pushed the statutory result to a loss.
FY27 guidance of about 5% underlying NPAT growth, with flat revenue, beat some forecasts and the shares jumped about 18% on the day. CSL Vifor revenue is expected to fall about 25% in FY27.
4. CSL Share Price in 2026: Where It Stands
With only weeks left in 2026, a year-end "target" is not meaningful. The stock was at A$198.5 on 19 Nov 2026. The stock has rallied strongly since the August results.
5. CSL Share Price Target 2027: A$166 – A$239 (Base A$202)
Based on FY2027 EPS of A$9.20 / A$9.20 / A$9.20 (bear / base / bull). What to watch: Plasma collection costs and margins.
6. CSL Share Price Target 2028: A$171 – A$268 (Base A$219)
Based on FY2028 EPS of A$9.48 / A$9.94 / A$10.30 (bear / base / bull). What to watch: CSL Vifor revenue decline.
7. CSL Share Price Target 2029: A$176 – A$300 (Base A$236)
Based on FY2029 EPS of A$9.76 / A$10.73 / A$11.54 (bear / base / bull). What to watch: Seqirus vaccine demand.
8. CSL Share Price Target 2030: A$181 – A$336 (Base A$255)
Based on FY2030 EPS of A$10.05 / A$11.59 / A$12.93 (bear / base / bull). What to watch: Progress of the A$1 billion buyback.
9. Key Metrics
| Metric | Value | Why it matters |
|---|---|---|
| Forward EPS (est.) | ~A$9.20 | Starting point |
| Forward P/E | 21.6× | Below its historical premium |
| Dividend yield | 2.1% | Income |
| FY27 NPAT guidance | ~+5% | Growth reset |
10. ASX Peer Comparison
| Company | Price (A$) | Trailing P/E | Forward P/E | Dividend yield |
|---|---|---|---|---|
| BHP | 52.16 | 18.7× | 14.5× | 5.3% |
| Commonwealth Bank (CBA) | 173.08 | 26.7× | 25.7× | 2.9% |
| CSL | 198.50 | n/a (statutory loss) | 21.6× | 2.1% |
| Fortescue (FMG) | 13.36 | 9.9× | 15.4× | 8.1% |
| Woodside (WDS) | 30.37 | 13.1× | 10.6× | 5.2% |
Prices as of 19 Nov 2026 (ASX, midday). Source: StockAnalysis.
The Key Debate on CSL
The bull argument: CSL is a global leader in plasma therapies with high barriers to entry. FY27 guidance shows a return to growth, plasma margins are recovering, and the valuation is much lower than its historical average.
The bear argument: Recent years have brought large write-downs and repeated guidance cuts. CSL Vifor is shrinking, vaccine demand in the US has weakened, and the market may not trust management until margins clearly recover.
How to tell which side is winning: Watch CSL Behring's gross margin and whether FY27 guidance is met or raised at the half-year result.
11. Risks That Would Break the Base Case
- Further impairments.
- Weaker US vaccine demand.
- Plasma competition and pricing.
- Currency moves (USD reporting, AUD share price).
12. What the Numbers Suggest
Our base case of A$255 assumes a gradual recovery. CSL used to trade above 30× earnings; the bull case only partly returns to that level.
This is a framework, not a recommendation. Your own decision should depend on your time horizon, risk tolerance and existing holdings.
13. FAQs on CSL Share Price
What is the CSL share price target for 2027?
Our base case is A$202, assuming 8% annual EPS growth and a 22× P/E. The range is A$166 (bear) to A$239 (bull).
What is the CSL share price target for 2030?
Base case A$255; range A$181 to A$336. It assumes FY2030 EPS of about A$11.59.
Why did CSL report a loss?
Mainly because of US$7.1 billion of pre-tax impairments, not because the core business became unprofitable.
What is CSL's FY27 guidance?
About 5% growth in underlying NPAT with broadly flat revenue at constant currency.
Sources
Prices, valuation multiples and results were checked on 18–19 November 2026. We review each target after the company's next results. Prepared by the ChartMyWealth Editorial Team using the method described in our methodology.
Disclaimer: This article is for educational purposes only and is not investment advice or a recommendation to buy or sell any security. Price targets are scenario estimates based on the stated assumptions and may not materialise. Please consult a licensed financial adviser (AFSL holder) before making investment decisions.
Leave a comment
Your email address will not be published. Required fields are marked *
